[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cannabinoid-hyperemesis-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cannabinoid-hyperemesis-syndrome":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100648796","early-phase-1-haloperidol-for-outpatient-symptom-management-in-patients-diagnosed-with-cannabinoid-hyperemesis-syndrome-in-the-emergrency-department-100648796",false,"NCT07726069","Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department","Inclusion Criteria:\n\n\\- Patients who meet ROME-4 diagnostic criteria for cannabinoid hyperemesis syndrome\n\nExclusion Criteria:\n\n* Already on dopamine agonist\u002Fantagonist therapy for another condition\n* Parkinson's disease\n* Lewy body dementia\n* Men with QTc \\> 450\n* Women with QTc \\> 460\n* Patients with documented allergy to haloperidol\n* Patients with known functional prolactinomas\n* Patients who are breastfeeding\n* Patients under the age of 18\n* Patients who are pregnant\n* Patients who are in the prison system\n* Patients who are unable to consent",true,"ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","Patients diagnosed with cannabinoid hyperemesis syndrome that are safe for discharge from the emergency department will be sent an outpatient prescription for haloperidol to be used as needed at home. The study goal is to see if having this medication available helps to prevent return emergency department visits for recurrent or persistent symptoms.",[26],"Cannabinoid Hyperemesis Syndrome",[28,29,30,31],"chs","cannabinoid hyperemesis syndrome","haldol","haloperidol","NOT_YET_RECRUITING","2026-08-13",{"date":35,"type":36},"2026-08-17","ACTUAL",{"date":38,"type":20},"2026-11",{"date":40,"type":20},"2028-01",{"name":42,"class":43},"University of Illinois at Chicago","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":66,"locationsCount":44},"100611869","phase-3-comparing-haloperidol-to-olanzapine-in-the-treatment-of-suspected-cannabinoid-hyperemesis-in-the-emergency-department-100611869","NCT07246187","Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department","CH2O","Inclusion Criteria:\n\n* subjects must meet ONE of the below criteria AND are a near-daily to daily user of cannabis by inhalation for greater than or equal to 6 months.\n\n  1. Have documented previous diagnosis of cannabinoid hyperemesis, or\n  2. Report (or on chart review) greater than or equal to 3 episodes of emesis in a cyclic pattern separated by greater than 1 month during the preceding 2 years, or\n  3. The provider suspects cannabinoid hyperemesis as the primary or equally likely primary diagnosis.\n\nExclusion Criteria:\n\n* Ineligible subjects include age less than 18 years, weight less than 50 kg, pregnancy, daily benzodiazepines use, prolonged QTc interval on the electrocardiogram (ECG), breastfeeding mothers, previously known allergy to or intolerance of either study drug, subjects taking drugs that are contraindicated with haloperidol or olanzapine, subjects with Parkison's Disease, subjects already taking haloperidol, olanzapine, or other antipsychotics","100 Years",{"count":54,"type":20},114,[56],"PHASE3","The aim of the study is to identify which medication (haloperidol or olanzapine) is most effective in treating nausea and abdominal pain associated with cannabinoid hyperemesis using a 10-point visual analog scale with intervals of 0.5.",[26],"RECRUITING","2025-11-17",{"date":62,"type":36},"2025-11-24",{"date":64,"type":36},"2025-11-06",{"date":38,"type":20},{"name":67,"class":43},"Mercy Bon Secours Saint Vincent Medical Center",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":78,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":5},"100566878","cannabinoid-hyperemesis-syndrome-prospective-multicenter-study-of-patients-admitted-to-adult-emergency-departments-in-maine-et-loire-100566878","NCT06660901","Cannabinoid Hyperemesis Syndrome. Prospective Multicenter Study of Patients Admitted to Adult Emergency Departments in Maine-et-Loire.","CANN-AIE","Inclusion Criteria:\n\n* Patient aged 18 to 65 years,\n* Consulted the Maine et Loire adult emergency department for abdominal pain and\u002For vomiting for the 1st time during the study period.\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Patient unable to answer questionnaire (allophone, under guardianship, under protection, incapable of age, under legal proceedings)\n* Pregnant women","65 Years",{"count":77,"type":20},3000,"3 Months","OBSERVATIONAL","Cannabinoid hyperemesis syndrome (CHS) is characterized by incoercible abdominal pain and vomiting in patients with chronic cannabis use. Patients are relieved by hot showers, an easily performed diagnostic test.\n\nThe prevalence of this syndrome in France is not well known. A single French study from 2021, carried out in two Marseille emergency departments, estimated a 1.6% prevalence of CHS (48 cases \u002F 2848 patients) in patients consulting for acute abdominal pain with no etiology found over a 10-month period.\n\nCannabis is the most widely used illicit substance in France. France is also the second biggest cannabis consumer in Europe, with around 11% of the French population currently using the drug (use within the year).\n\nDespite growing attention to CHS, the diagnosis and management of this syndrome remains difficult, with repeated visits to emergency departments often required before a diagnosis is made. What's more, once the diagnosis has been made, the severity of symptoms can lengthen the emergency room length of stay.\n\nMain objective:\n\nTo estimate the incidence of cannabinoid hyperemesis syndrome among patients admitted on a first visit for abdominal pain and\u002For vomiting to the Maine et Loire emergency department.\n\nPrimary endpoint:\n\nThe incidence of cannabinoid hyperemesis syndrome among patients presenting with abdominal pain and\u002For vomiting, consulting adult emergency departments in Maine et Loire. Cannabinoid hyperemesis syndrome will be considered in all patients admitted for abdominal pain and\u002For vomiting, who are regular cannabis users (weekly use for more than 6 months declared by questionnaire) and in whom no other etiology is accepted after any additional examinations.\n\nResearch plan and procedure:\n\nIt is an observational, prospective, multi-center cohort study. Participation in the study is offered to any emergency room patient who meets all inclusion criteria and none of the non-inclusion criteria. Patients are included after reading the information note. Consent is obtained on a no-objection basis.\n\nA questionnaire is given to participants via a QR code with an identification number generated by the investigating physician. This QR code opens an online questionnaire that the patient can fill in while in the emergency department. In the absence of access to the QR code (no cell phone), the questionnaire will be given to the participant in paper format by the investigating physician. It will be collected at the end of the inclusion visit.\n\nParticipants who have revealed cannabis use (at least 1 time per week for at least 6 months) via the questionnaire are followed up at 3 months (+\u002F- 15 days) by telephone to assess the evolution of symptoms, any recurrences, medical treatment and whether or not cannabis has been withdrawn.\n\nInclusion criteria:\n\n* Patients aged 18 to 65 years,\n* Consulted an adult emergency department in Maine et Loire for abdominal pain and\u002For vomiting for the 1st time during the study period.\n\nNon-inclusion criteria:\n\n* Refusal to participate in the study\n* Patient unable to answer the questionnaire (allophone, under guardianship, under protection, incapable of major age, in the process of legal proceedings)\n* Pregnant women\n\nNumber of research participants:\n\nAt present, there are no data on the incidence of CHS in the French literature. In order to assess the number of subjects required, we made a projection based on the only French study to date. In this study, carried out in two departments in Marseille, the percentage of patients with CHS among those consulting the emergency department for acute abdominal pain was 1.6%. Thus, assuming that the proportion of the event will be identical to that of the study carried out in Marseille, i.e. 1.6%, it would be necessary to recruit 3,000 people with abdominal pain and\u002For vomiting to have around 50 patients with CHS.\n\nResearch duration:\n\nInclusion period: 12 months Duration of participation: 3 months +\u002F- 15 days (for patients with CHS) Study duration: 15 months",[82,26],"D000096704",[84,85,86,87,88,89],"marijuana","cannabis","Recurrent vomiting","nausea","abdominal pain","compulsive hot bathing behavior","2025-08-21",{"date":92,"type":36},"2025-08-28",{"date":94,"type":36},"2025-07-25",{"date":96,"type":20},"2026-10-31",{"name":98,"class":99},"University Hospital, Angers","OTHER_GOV"]